Moleculin Biotech, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2017. The company is a preclinical-stage oncology drug developer with no product revenue.
Financial results and liquidity
| Metric | Three months ended June 30, 2017 | Six months ended June 30, 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $515,000 | $1.199 million |
| General and administrative expense | $800,000 | $1.649 million |
| Operating loss | $1.320 million | $2.856 million |
| Net loss | $3.424 million | $3.754 million |
| Net loss per share | $0.19 | $0.23 |
| Operating cash used | Not separately reported | $3.323 million |
- At June 30, cash and cash equivalents were $9.272 million, versus $5.007 million at December 31, 2016. Current assets were $10.081 million and current liabilities $1.830 million.
- Financing provided $7.592 million in the first half, including $4.460 million net proceeds from the February offering and $3.132 million from warrant exercises. Cash increased by $4.265 million during the period.
- Convertible notes were fully converted by June 22; no convertible notes remained at June 30. Total liabilities were $1.980 million, including a $1.185 million current warrant liability.
- There is no meaningful operating margin to assess because the company had no revenue. The filing reports losses, not profit.
Changes versus the prior comparable periods
- Second-quarter operating expenses rose to $1.320 million from $724,000 in 2016; first-half expenses increased to $2.856 million from $1.044 million. Management attributed the increases mainly to expanded R&D activity, staffing, clinical-trial preparation, and professional costs.
- First-half net loss widened to $3.754 million from $1.071 million. The 2017 results include significant warrant fair-value movements that were not present in 2016, as well as increased operating costs.
- First-half operating cash used increased to $3.323 million from $1.645 million. Financing cash provided declined to $7.592 million from $8.862 million in the 2016 period, which included the IPO.
- Common shares outstanding increased to 20,164,854 at June 30 from 12,164,852 at year-end 2016, reflecting the follow-on offering, warrant exercises, debt conversions, and shares issued for services.
Outlook, risks, and unusual items
- Funding and going concern: Management estimated cash would fund planned operations through the second quarter of 2018, subject to clinical progress and drug-product needs. Separately, the notes state that cash was sufficient into, but not beyond, the near term and that substantial doubt existed about the company’s ability to continue as a going concern. Management expects further capital will be needed; additional financing may be unavailable or dilutive.
- Annamycin: The FDA requested protocol revisions, additional information, and chemistry, manufacturing and controls data after the company submitted an IND in February 2017. The company withdrew the application pending CMC data and expected to resubmit in time for the IND to take effect by the end of September 2017. Delays could postpone trial initiation. The planned Phase I/II trial adds time and expense; management anticipated announcing trial results sometime in 2018. Annamycin received FDA Orphan Drug designation for AML. Its drug substance lacked existing patent protection; a new MD Anderson technology license and intended patent applications were reported in July, with no assurance patents would issue.
- Other programs: A physician-sponsored WP1066 trial remained on hold pending GMP documentation; the company said it could support, but not control, the trial. WP1122 remained in preclinical development. The company also reported promising preclinical findings for WP1234, which are not clinical evidence of efficacy.
- Warrant accounting: First-half results included a $2.283 million loss from changes in warrant fair value and a $1.238 million gain from warrant expirations. These are noncash accounting items and made reported net loss more volatile. The warrant liability was valued using Level 3, unobservable inputs.
- Subsequent events: After quarter-end, the company reported that approximately 450,000 additional Series A warrants had been exercised, with approximately $675,000 expected before expenses once processing was complete. It also reported regaining Nasdaq minimum-bid-price compliance in July.
- Controls and contingencies: Management concluded disclosure controls were not effective because of a material weakness in segregation of accounting duties. No pending legal proceedings were reported. The company has license-related maintenance, milestone, royalty, and research obligations.
Key facts for investors to verify
- Reconcile the MD&A’s second-quarter net-loss discussion, which describes a $2.3 million loss, with the financial statements’ reported $3.424 million net loss for the quarter.
- Track the timing and completeness of CMC work, IND resubmission and effectiveness, site approvals, and Annamycin trial initiation.
- Assess whether the stated cash runway through Q2 2018 is consistent with the going-concern disclosure and actual spending and enrollment needs.
- Monitor warrant exercises, proceeds received, remaining warrant liabilities, and potential share dilution.
- Follow remediation of the material weakness in segregation of duties and progress toward effective disclosure controls.